Tyrosine specific protein kinase activity was determined in 70 speci mens of the human mammary gland. These included 28 cancers of the breast, 21 benign breast diseases, and 21 normal breast tissues. We measured tyrosine kinase activity in the cytosol fraction and in the membrane fraction of the homogenates. In addition cytosolic aldolase activity was measured. Tyrosine kinase activity was determined using poly(glutamic add :tyrosine = 4:1) as an artificial substrate. Cancers of the breast exhibited considerable higher tyrosine kinase activities in both cytosol and membrane fractions, compared to benign breast tumors (P â‚¬¿ 0.001). Benign tumors demonstrated increased activities in cytosol in comparison to normal breast tissues (P < 0.001). Furthermore, there appears to be a strong association of an enhanced expression of activity of tyrosine kinase in cytosol of primary carcinomas and early systemic relapse. In combination with aldolase activity a nearly complete discrim ination is achieved between malignant specimens on one hand and benign and normal tissues on the other.
INTRODUCTION
At present the best indicator of the biological behavior of breast cancer is the presence and number of axillary lymph node mÃ©tastases.In addition several other morphological and biochemical features with some value as a prognostic factor have been described. However, there is a need for more and better markers of malignancy and prognosis (1) (2) (3) (4) (5) (6) (7) .
From a clinical point of view attention should be directed (a) to the establishment of additional prognostic factors, (/>) to the possibility of using markers to differentiate benign from malig nant lesions, and (c) to the identification of the benign lesions that signify an increased risk for future development of malig nancy.
Tyrosine protein kinases are enzymes that phosphorylate tyrosine residues of protein substrates. Tyrosine phosphorylation is now recognized as an important regulatory mechanism in response to a number of processes including the action of several growth factors and oncogenes (8) (9) (10) . Slamon et al. (11) demonstrated HER 2/neu oncogene amplification in human breast cancer. The HER-2/wew oncogene is related to but not identical with the c-erbB oncogene (11) . The HER-2/neu on cogene codes for a protein which has an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. Amplification of this gene in human breast cancer is associated with time to disease relapse and with overall patient survival (11) . c-erbB codes for the EGF2 receptor. A correlation of c-erbB-2 gene amplification and protein expression in human breast cancer with nodal status and nuclear grading has been observed (12) . EGF has been demonstrated to increase tumor growth in cultures of primary human breast cancers (13) . Fur thermore, the presence of EGF receptors in human breast Received 1/21/88; revised 8/22/88; accepted 10/20/88. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1To whom requests for reprints should be addressed. 2The abbreviations used are: EGF, epidermal growth factor; poly(Glu:Tyr, 4:1), poly(glutamic acid:tyrosine, 4:1); DTT, dithiothreitol. cancers has been demonstrated and is associated with metastatic potential (13, 14) . The internal domain of the EGF receptor has tyrosine specific protein kinase activity (8, 15) . The v-erbB protein is a truncated EGF receptor, consisting of the transmembrane and the internal domain (10) .
Expression of these oncogenes in breast cancer may be re flected in increased tyrosine kinase activity. Actual measure ment of tyrosine kinase activity has been made possible by the use of artificial substrates. Initially these were composed of amino acid sequences related to the phosphorylation site of the various tyrosine kinases coded for by oncogenes. We deter mined tyrosine kinase activity in breast tumors as well as in normal breast tissues using poly(Glu:Tyr = 4:1) as an artificial substrate (16, 17) .
It is well established that malignant cells usually exhibit a high glycolytic rate even under aerobic conditions. Recently we demonstrated significantly increased glycolytic enzyme activi ties in malignant breast tissues, in comparisons to normal and benign breast tissues (18) . In discriminant analysis the function giving the best fit to the histolÃ³gica! data was mainly based on the activity of the enzyme aldolase and in a lesser degree on the expression of 7-enolase. The discrimination achieved showed a higher percentage of correct classifications for both benign and malignant disease.
Here we present the results of the determination of tyrosine kinase activity in the cytosol fraction and the membrane fraction of homogenates of normal, benign, and malignant breast tis sues, in combination with the determination of aldolase activity. With this method it is possible to discriminate normal and benign breast tissues from breast cancers. Furthermore it ap pears that tyrosine kinase activity is higher in biologically more aggressive tumors.
MATERIALS AND METHODS
Patients and Pathology. The patients were grouped according to histology: juvenile hypertrophy of the breast; benign breast disease; and carcinomas of the breast. Specimens were obtained when a benign breast lump was excised. In the case of malignancy, the tumors were either biopsied or treated surgically. The specimens of breast tissue from patients with juvenile hypertrophy were obtained when a reduction mammoplasty was performed. These specimens did not show any abnormality on histolÃ³gica! examination and were therefore accepted to represent the enzyme activities of normal breast tissue.
Two series of patients were investigated. In the second series artificial substrate from a different batch had to be used for the tyrosine kinase assays, resulting in lower figures for the activities measured. The two series had to be analyzed separately.
The first series (n = 40) consisted of 10 patients with juvenile hypertrophy of the breast, 10 patients with benign disease, and 20 patients with carcinoma of the breast. The histology of the specimens with benign disease was fibroadenoma (n = 3) and fibrocystic disease (n = 7), all of which demonstrated proliferative features (19) . Clinical and pathological data for the patients with malignant disease are summarized in lymph node mÃ©tastaseswere detected. In this first series a median duration of follow-up of 17.5 months has been reached (range, 11-64 months). At present 6 of the 18 patients with locoregional disease at presentation have relapsed with systemic disease.
The second series (n = 30) consisted of 11 patients with juvenile hypertrophy, 11 patients with benign disease, and 8 patients with carcinoma of the breast. The histology of the specimens with benign disease was fibroadenoma (n = 5) and fibrocystic disease (n = 6) of which 4 specimens showed proliterative features (19) . For clinical and pathological data for the patients with carcinoma of the breast, see Table 1 . For 3 carcinoma patients no histopathological axillary nodal status is known: the 2 patients with systemic disease at presentation were not treated surgically; 1 patient underwent mastectomy without axillary dissection. Of the remaining S patients, 1 had tumor positive axillary lymph nodes.
HistolÃ³gica! diagnosis was made according to WHO criteria (20) . In 12 malignant specimens (7 specimens from the first series, 5 specimens from the second series) a sufficient amount of tissue was available to allow histopathological evaluation of tumor tissue in juxtaposition to the enzymologically assayed part. To determine tissue heterogeneity, the amounts of the various tissue components present were estimated (Table 2) . Four categories were used: fat; stromal elements; nontumorous epithelium; tumorous epithelium. The proportion of each was expressed as percentage of the total. For this purpose a "lattice" on the microscopic field was used, a method described previously (18) . In this way also the composition of 11 specimens of normal breast tissue was evaluated (all from the second series) and 9 specimens with benign disease (2 from the first series and 7 from the second series).
Sample Preparation. Table 2 Composition of tissue in juxtaposition to the enzymological assayed part of the specimens The proportion of each component present was noted as percentage of the total. Four categories were used: fat; stromal elements; nontumorous epithelium; tumor epithelium. The mean percentages of the latter 3 categories are presented (range in parentheses).
Stromal
Nontumorous Tumorous elements epithelium epithelium Normal breast tissues (n -11)Benign breast disease (n â€"¿ 9)Breast cancer (n = 12)72.5%(55-90)72%(5-90)49%(10-75)7%(1-15)11.5%(5-20)2%(0-15)35% directly from surgery. Part of it was used for frozen section and paraffin sections; the remaining parts were stored immediately at â€"¿ 80Â°Cfor estrogen and progesterone receptor assay and enzymological evaluation.
Before enzymological assay the specimens were first cleared of fat and debris. All specimens had a wet weight of 150-250 mg.
Samples were homogenized in 4 volumes 10 mM Tris-HCl (pH 7.4) containing 0.25 M sucrose, 1 mM MgCl2, 1 mM EDTA, 1 mM diisopropylfluorophosphate, 1 mM phenylmethylsulfonyl fluoride, 1 mM DTT, and aprotinin (0.5 mg/ml). All debris and nuclei were removed by centrifugation at 800 x g for 10 min (4Â°C).The supernatant was centrifuged at 150,000 x g for 30 min (4Â°C). The 150,000 x g super natant fraction was used as the cytosolic fraction for assay of tyrosine kinase activity.
The 150,000 x g pellet (membrane fraction) was resuspended in 50 mM Tris-HCl (pH 7.5), containing 20 mM magnesium acetate, 5 mM NaF, 1 mM EDTA/ethyleneglycol bis C8-aminoethyl etherJ-tyJV-tetraacetic acid, 1 mM DTT, 30 MMsodium o-vanadate and 0.5% Nonidet P-40. After sonication twice for 15 s (0Â°C), the preparation was centri fuged at 150,000 x g for 30 min (4"C) and this supernatant (solubili/ed membrane fraction) was also assayed for tyrosine kinase activity.
Determination of Tyrosine Kinase Activity. Phosphorylation of en dogenous cytosolic and solubili/ed membrane protein (3 Mg/assay) was carried out at 20"C in a total volume of 64 n\ containing 50 mM Tris- Tyrosine kinase activity was determined in the above system by adding poly(Glu-Tyr, 4:1) (Sigma, Chemical Co., St. Louis, MO) as substrated (278 MM).After stopping the reaction by adding 17.5 mM ATP and 70 mM EDTA samples were spotted on Whatman No. 3 MM paper, precipitated, and washed several times in 10% trichloroacetic acid and 100 mM NaiPjCh. Paper discs were then washed in ethanol:ether (1:1) and 100% ether. Scintillation fluid was added and the samples were assayed for radioactivity.
Tyrosine kinase activity was corrected for endogenous phosphorylation, measured as described above in the absence of added substrate. Tyrosine kinase activity is expressed as pmol ATP/min/mg protein.
The protein content was determined according to the method of Lowry et al. (21) .
The protein tyrosine kinase assay is linear as a function of time and protein up to 30 min and 10 Mgprotein, in the cytosol as well as the paniculate fractions of normal breast tissues and of benign and malig nant breast tumors.
Determination of Aldolase Activity. Aldolase (D-fructose 1,6-diphosphate D-glyceraldehyde-3-phosphate lyase; EC 4.1.2.13) activity deter mination was carried out as described previously (18) . One unit of activity was defined as that amount of enzyme which catalyzes the formation of 1 niuol of product/min in standardized conditions. Spe cific activities are expressed as units/mg protein.
Statistical Analysis. Differences between groups were tested using Student's t test. To normalize the distribution of values, the activities were first transformed in natural logarithms (22) .
RESULTS
Tyrosine kinase activities in the cytosolic as well as in the solubili/ed membrane fractions of normal breast tissues, benign breast disease, and carcinomas of the breast are presented in Table 3 . Tyrosine kinase activities in tumors, benign and malig nant, are higher compared to those of normal tissues of the breast. Within the group of tumors the cancers have higher activities compared to benign tumors. For cytosolic tyrosine kinase activity differences between normal and benign as well as between benign and malignant are highly significant. In contrast, the difference between membrane bound tyrosine ki nase activity in normal and benign breast tissue is less well developed, whereas benign compared with malignant breast tissue gives a highly significant difference.
During the course of our investigations we noticed batch-tobatch differences in the absolute levels of tyrosine kinase activity when using different batches of poly(Glu:Tyr, 4:1). The batches also varied in their mean molecular weights. We therefore had to divide our patient material in two series. Although the mean levels of tyrosine kinase activity were slightly lower in the second series, the results of the first series were completely reproduced.
In both series some overlap exists in the activities observed in normal, benign, and malignant specimens. The tyrosine kinase activity in cytosol produces a better separation between the specimens, compared with the membrane bound tyrosine kinase activity. The 2 series taken together the cytosolic tyrosine kinase activity of 4 of 21 benign specimens overlap with carci nomas. One of these was also demonstrated to be heavily infiltrated with lymphocytes. Four of 28 malignant specimens overlap with benign tumors. Discrimination on the basis of membrane bound tyrosine kinase activity shows 9 of 21 benign specimens in "malignant range," including the specimen dem onstrating the lymphoid infiltration, whereas 16 of 28 carci nomas overlap with "benign range." In these relatively small series no significant differences could be observed between histologie-aÃsubgroups of carcinomas, or benign diseases. Al dolase activities are highest in carcinomas. Benign tumors show an intermediate position, while normal tissues have the lowest activity levels. All differences are significant (P ss 0.02).
Separation of the three groups according to their histology can thus be achieved either by tyrosine kinase activity in the cytosolic fraction or by aldolase activity. However, Fig. 1 100.00 T.K. cylosol activity Fig. 1 . Discrimination of normal breast tissue, benign breast disease, and breast cancer by plotting cytosol tyrosine kinase (T.K.) activity against aldolase activity of each specimen separately. Cytosol tyrosine kinase activity is presented logarithmically on the X-axis, aldolase activity is presented logarithmically on the Y-axis. â€¢¿ , normal breast tissue; A, benign breast disease; A, breast cancer.
dem-
onstrates an improved discrimination of the groups of the first series, by plotting cytosol tyrosine kinase activity of each spec imen against its aldolase activity. In this way a fair discrimi nation is reached. Normal, benign, and malignant specimens concentrate each in 1 of 3 zones with, in this small series, relatively few overlaps. Of clinical interest is distinguishing malignant from benign specimens. The benign specimen in proximity of the main group of carcinomas is a specimen with the histology of fibroadenoma exhibiting a high aldolase activ ity. The carcinoma in the benign range shows low expression of activity of both cytosolic tyrosine kinase and aldolase. A possible contamination with nontumorous epithelium account able for low activities in this specimen can be neither proved nor denied because a histolÃ³gica! evaluation of tissue in juxta position to the enzymological assayed part is not available. Plotting the specimens of the second series (graph not shown), only one benign specimen overlapped with the carcinomas. The histology observed in this specimen was a fibrocystic disease with proliferative features; in addition it proved to be heavily infiltrated with lymphocytes. This contamination with lympho cytes readily explains the high activities measured, inasmuch as normal lymphocytes demonstrate extremely high activities for tyrosine kinase in both cytosol and membrane bound (results not shown). We considered the possibility that the level of tyrosine kinase activity reflects the grade of malignancy of breast cancer. We analyzed the natural history of the disease in the patients of the first series. Because of the relatively short duration of followup only disease free survival was used as end point of this analysis. At a median follow-up of nearly 18 months 6 of 18 patients with operable disease have relapsed. Fig. 2 displays the disease free survival curves for the population stratified into one group having tyrosine kinase activities in cytosol lower than or equal to the mean of all patients in the first series and a second group with activities higher than the mean. The one patient who relapsed with a tyrosine kinase activity in cytosol lower than the mean is the same patient that had to be plotted in a benign range (Fig. 1) . The median follow-up in the group with lower or equal activities for tyrosine kinase in cytosol is approximately 10 weeks shorter compared to the median fol low-up for the group with the higher activities. Nevertheless, even this shorter median duration of follow-up exceeds the longest disease free survival of the patients that relapsed. It Fig. 2 . Disease free survival curves of the patients with operable cancer of the breast from the first series (n = 18). The patients are stratified into a group with tyrosine kinase activity in cytosol below or equal to the mean of the total number of breast cancer patients of the first series and a second group with tyrosine kinase activity in cytosol higher than the mean.
, group of patients with low activities for tyrosine kinase in cytosol;
, patient group with high activities. The curves for each group are drawn for the period of median duration of followup; in the remaining patients of each group no events occurred afterwards.
therefore would appear that a high activity of tyrosine kinase in cytosol is accompanied by a more aggressive biology of the tumor.
Other factors known to be important in the prognosis of breast cancer are the size of the tumor, the axillary nodal status, hormonal receptor status, and age. In the first series no signif icant differences were found between groups when stratified on diameter of the tumor (smaller than or equal to 2 cm and larger than 2 cm) or between the groups with and without axillary lymph node mÃ©tastases; also no differences were noted between premenopausal and postmenopausal patients and no correla tion was seen between tyrosine kinase activity and level of estrogen receptor binding. However, this present series is small. In this respect it is noteworthy that a clear prognostic separation appears when a stratification on tyrosine kinase activity in cytosol is used.
DISCUSSION
Tyrosine specific protein kinase activity is associated with products of several viral transforming genes and their cellular homologues, as well as with a number of growth factor receptors (8) (9) (10) . This paper is an attempt to assess the relevance of overall tyrosine kinase activity for the diagnostic and/or prog nostic classification of human mammary tumors. Recently it has been demonstrated that protein tyrosine kinases phosphorylate synthetic random copolymers of tyrosine and glutamic acid (16, 17) . In this study poly(Glu:Tyr, 4:1) was used as an artificial substrate.
Our data show a 25-fold increase of tyrosine kinase activity Â¡n the cytosol fraction of breast cancer specimens, when com pared to normal breast tissue. For membrane bound tyrosine kinase the increase in breast cancer specimens compared to normal breast tissue is 4-to 8-fold. Benign tumors take an intermediate position: compared to normal the increase in tyrosine kinase activity in the cytosolic fraction is 4-fold; for membrane bound tyrosine kinase activity the increase is 2-fold. In the first series, at a median follow-up of nearly 18 months, a strongly increased risk of relapse is demonstrated for the group with higher activities for tyrosine kinase in the cytosol.
Tissue heterogeneity has been recognized to influence the level of activity that is measured Â¡nenzymological assays in breast cancer specimens (18, 23) . The best method at hand to assess the composition of the enzymological assayed part of the tumor is to evaluate histologically the parts in juxtaposition. In this study in nearly half of the specimens a sufficient amount of tissue was available to allow this evaluation (Table 2) . Com paring benign with malignant tumors the increase in tyrosine kinase activity exceeds the increased presence of epithelium, normal and malignant. Therefore, the increased tyrosine kinase activity in cytosol in malignant breast tissues is not in all likelihood explained by the increased presence of epithelium in the malignant specimens. Moreover, we could not establish a significant correlation between the amounts of nontumorous and/or tumorous epithelium present and the activities of tyro sine kinase that were measured.
It is tempting to speculate on the origin of tyrosine kinase activity in breast cancers. In human breast cancer specimens amplification of an oncogene that codes for tyrosine kinase activity has been described. Slamon et al. (11) examined 189 breast cancers; 53 demonstrated amplification of the HER-2/ neu oncogene. In an earlier study he demonstrated the expres sion of c-fes oncogene in 3 of 4 breast cancer specimens exam ined (24) . The c-fes transcript also has tyrosine kinase activity (8, 9) . Correlation of HER-2/neu gene amplification with sev eral disease parameters demonstrated a highly significant cor relation with overall survival and time to relapse (11) . It is noteworthy that only 4 specimens of 189 exhibited EGF recep tor gene amplification.
Berger et al. (12) analyzed 51 primary human breast cancers for amplification of the c-erbB-2 protooncogene. In 13 of 51 DNA isolates a 2-to 15-fold amplification of this protoonco gene was demonstrated. Also c-erbB-2 protein specific antibod ies were used to stain paraffin embedded slides of these tumors. In 10 of 12 tumors demonstrating amplification, the c-erbB-2 protein was observed. In addition, 13 of 35 specimens with a single copy c-erbB-2 stained positively for this protein. Positive staining was significantly associated with nodal status and nuclear grade of malignancy.
Sainsbury et al. (14) assayed by radioligand binding and monoclonal antibody techniques for the presence of EGF recep tors in a series of 104 primary breast cancers and 14 lymph node mÃ©tastases. Of the primary cancers 35 were EGF receptor positive and 10 lymph node mÃ©tastaseswere EGF receptor positive. They demonstrated a significant inverse relationship between the presence of EGF receptors and the presence of estrogen receptors in primary tumors. Also EGF receptors were found in a greater proportion of the mÃ©tastasesthan in primary tumors (14) . In vitro studies show enhancement of growth in cell cultures of human breast cancers when EGF was added to the medium ( 13) . Other mitogenic growth factors have been documented to have a growth stimulating effect on breast cancer cell lines (26) . Several of these receptors have tyrosine kinase activity (8) . It is to be noted that all tyrosine kinase activity due to growth factor receptors is plasma membrane bound. Also the HER-2/neu protein is plasma membrane bound. Only the c-fes protein has activity both in the cytosol fraction and in the membrane fraction (9) .
The rise in expression of tyrosine kinase activity occurs in both the cytosol and the membrane fractions. However, the increase in activity has its greatest extent in the cytosol. Nearly all of the known sources for tyrosine kinase activity are bound to the plasma membrane. At this moment the explanation for this clearly developed difference is only speculative. Perhaps the role of c-fes expression in breast cancer is more important than is understood at present. There is a distinct possibility that oncogen products not yet described do contribute to the tyrosine kinase activity that is measured. It cannot be excluded that the major part of the activity measured in the cytosol originates from the plasma membrane and has been detached into the cytosol during sample preparation. Perhaps the cytosol fraction partially stems from internalized membrane receptors or from newly synthesized receptors in transit to the membrane.
Our experience in earlier work on glycolytic enzymes in breast cancer prompted us to include determination of aldolase activity in the present research. Using discriminant analysis on a panel of glycolytic enzymes to separate benign from malignant le sions, the aldolase activity proved to be the major contributor to the discriminant function (18) . Combining aldolase activity and tyrosine kinase activity in cytosol produces a nearly com plete separation of the 3 groups (Fig. 1 ).
An analysis of events during follow-up of the first series of patients was performed at a median duration of follow-up of 18 months. A strongly increased risk of relapse is associated with a high activity of tyrosine kinase in cytosol. It is to be noted that an inverse correlation with the estrogen receptor measurements could not be demonstrated. This result contrasts with observations on the correlation between EGF receptors and estrogen receptors (14) . However, our study deals with 28 patients with cancer of the breast, divided over 2 series. Perhaps larger patient numbers are required before significant correla tions are to be observed.
From the data quoted it follows that in tumorigenesis of human breast cancer multiple protooncogenes and growth fac tor receptors associated with tyrosine kinase activity might be involved. Without completely knowing the exact origin of the tyrosine kinase activity that is measured, it may well be that the total of tyrosine kinase activity is associated with the biological potential of a tumor of the breast. We attempted a first analysis of the clinical relevance of our approach in 2 series with still rather limited patient numbers. The follow-up study excepted, all results obtained in the first series were completely repro duced in the second series. As no patient of the second series could be followed for more than only a few months, disease free survival curves were not calculated for the second series.
In conclusion we present data demonstrating an enhanced expression of tyrosine kinase activity in breast cancers, com pared to benign breast tumors, whereas benign disease shows higher levels of activity than normal breast tissue does. The increase in activity is more clearly developed in the cytosol fractions of the homogenates. There appears to be an enhanced expression of activity of tyrosine kinase in primary carcinomas that cause systemic disease. In combination with aldolase activ ity a nearly complete discrimination is achieved between malig nant specimens on one hand and benign and normal tissues on the other. It is attractive to research the diagnostic and prog nostic aspects of tyrosine kinase activity expression in breast cancer in a larger series of patients.
